Can-Fite BioPharma Ltd.

Can-Fite BioPharma Ltd. is a biopharmaceutical company, which engages in the development of drugs for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. Its product pipeline include Piclidenoson, Namodenoson, and CF602. The company was founded by Pnina Fishman and Ilan Cohn on September 11, 1994 and is headquartered in Petach-Tikva, Israel.

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q2 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

PETACH TIKVA, Israel--(BUSINESS WIRE)---- $CANF--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced the expansion of its Phase II COVID-19 study of Piclidenoson to two European countries, Romania and Bulgaria. The randomized, double blind, placebo-controlled study is evaluating the benefits of treatment of Piclidenoson plus standard supportive care

Can-Fite Expands its Phase II COVID-19 Study to Europe

Can-Fite BioPharma (NYSE: CANF) has initiated a series of preclinical studies required by regulators to support potential marketing registration filings for its drug candidates Piclidenoson and Namodenoson in the U.S. and Europe. As part of marketing applications in the U.S. and Europe, both regulators require specific preclinical data to be submitted along with the pivotal Phase 3 data.

Can-Fite Starts Preclinical Studies Required By FDA, EMA For Two Lead Drug Candidates Registration Filing

PETACH TIKVA, Israel--(BUSINESS WIRE)---- $CANF--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory and liver diseases, announced today that in preparation for anticipated potential marketing registration filings for its drug candidates Piclidenoson and Namodenoson in the U.S. and Europe, the Company has initiated a series of preclinical studies required by regulators. As part of a New Drug

Can-Fite Initiates Preclinical Studies Required by FDA and EMA for the Registration of its Two Lead Drug Candidates

Can-Fite BioPharma (NYSE: CANF) has completed pre-clinical studies demonstrating that a Cannabidiol (CBD)-rich T3/C15 cannabis fraction induces inhibition of liver cancer cell growth. The company's lead drug candidate Namodenoson is expected to enter the Phase 3 study in Q4 2021.

Can-Fite Says Cannabinoid-Based Therapies Stop Liver Cancer Growth, Preclinical Studies Show

PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite: Cannabis Compound Inhibits Liver Cancer Growth in Preclinical Studies

Can-Fite: Cannabis Compound Inhibits Liver Cancer Growth in Preclinical Studies

PETACH TIKVA, Israel--(BUSINESS WIRE)---- $CANF--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced that the six existing distribution agreements it has signed for its advanced stage drug candidates Piclidenoson and Namodenoson in select territories have remaining potential milestone payments of up to approximately $130 million plus double digit ro

Can-Fite: Summary of Existing Out-licensing Deals with Potential Milestone Payments of up to approximately $130 million

PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite Reports 2020 Financial Results & Provides Clinical Development Update

Can-Fite Reports 2020 Financial Results & Provides Clinical Development Update

The stock price of Can Fite Biopharma (NYSE American: CANF) has increased by over 15% pre-market. This is why it happened.

CANF Stock Price Increases Over 15% Pre-Market: Why It Happened

AC Immune

Moderna

Moderna Inc. (NASDAQ: MRNA), AC Immune SA (NASDAQ: ACIU) and Can-Fite BioPharma Ltd. (NYSE: CANF) were among the early biotech movers Tuesday.

Why Can-Fite, Moderna, AC Immune Shares Are Rallying

Can-Fite Biopharma (CANF) stock is on the rise Tuesday after announcing a $42.7 million distribution rights deal with Ewopharma. The post CANF Stock: Why Are Can-Fite Biopharma Shares Skyrocketing Today?

CANF Stock: Why Are Can-Fite Biopharma Shares Skyrocketing Today?

The stock price of Can-Fite BioPharma Ltd. (NYSE American: CANF) is trading at over 70% pre-market.

CANF Stock Price Increases Over 70% Pre-Market: Why It Happened

PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite Signs $42.7 Million Out-Licensing Deal with Ewopharma

Can-Fite Signs $42.7 Million Out-Licensing Deal with Ewopharma

CanFite Biopharma Ltd (CANF) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

CanFite Biopharma Ltd (CANF) Upgraded to Buy: Here's Why

PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite Enrolls First Patient in Phase II COVID-19 Study Under FDA Protocol

Can-Fite Enrolls First Patient in Phase II COVID-19 Study Under FDA Protocol

Can-Fite BioPharma (NYSE: CANF) reports new data from Phase 2 trial evaluating namodenoson in advanced liver cancer, including the overall survival of nearly four years in two patients under treatment. Additional findings show the disappearance of ascites (abnormal buildup of fluid in the abdomen), normal liver function, and good quality of life.

Can-Fite BioPharma's Namodenoson Improves Liver Function, Long Term Data Shows

PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced new data from the Phase II advanced liver cancer study including overall survival of nearly 4 years in two patients who are under namodenoson treatment. Additional findings show disappearance of ascites, normal liver function and good quality of life. In

New Positive Data from Can-Fite's Liver Cancer Phase II Clinical Study with Namodenoson

PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite Announces Inhibition of Liver Fibrosis by Cannabis Compounds in Preclinical Studies

Can-Fite Announces Inhibition of Liver Fibrosis by Cannabis Compounds in Preclinical Studies

PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today published a webinar on Namodenoson in the treatment of NASH hosted by Can-Fite CEO Dr. Pnina Fishman and featuring Dr. Stephen Harrison, a Key Opinion Leader (KOL) in the treatment of non-alcoholic steatohepatitis (NASH). Can-Fite's drug candidate Namodenoson

Can-Fite's NASH Indication Highlighted in Webinar by KOL Dr. Harrison: “Namodenoson May Have Big Impact on NASH”

Can-Fite Biopharma  Ltd. was one of the sponsors for the Benzinga Global Small Cap Conference that took place on December 8-9, 2020.

Piclidenoson From Can-Fite Biopharma Shows New, Promising Developments For Psoriasis Treatment

PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite Announces Publication of Namodenoson Liver Cancer Study in Peer Reviewed Journal—Cancers

Can-Fite Announces Publication of Namodenoson Liver Cancer Study in Peer Reviewed Journal—Cancers

Petach Tikva, Israel--(Newsfile Corp. - January 4, 2021) - Can-Fite BioPharma Ltd. (NYSE: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced that Dr. Sari Fishman, the Company's Vice President of Business Development, will present at the Biotech Showcase™ Digital 2021 conference and conduct virtual one-on-one meetings with potential pharmaceutical distribution partners and investors during the conference which takes place from January...

Can-Fite to Present at Biotech Showcase Digital 2021

PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced it has received approval from the Medical Cannabis Unit of Israel's Ministry of Health to conduct pre-clinical studies on the effect of nanomolar concentrations of cannabinoid fractions on the proliferation and functionality of cancer, inflammatory a

Can-Fite Receives Israel Ministry of Health Approval to Conduct Research with Cannabinoids in Cancer, Inflammation and Obesity at the Company Discovery Labs

PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite Reports on Progress with its Namodenoson NASH Program

Can-Fite Reports on Progress With Its Namodenoson NASH Program

Can-Fite BioPharma Ltd. (CANF) CEO Pnina Fishman on Q3 2020 Results - Earnings Call Transcript

PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite Reports Third Quarter 2020 Financial Results & Provides Clinical Update

News for Can-Fite BioPharma Ltd. Stock (CANF)